MedTrace Logo

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

NCT04217356 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-01-26

No results posted yet for this study

Summary

The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis. This will be done by asking participants to choose the treatment that they prefer to receive (HCT or BAT) and then comparing the outcomes of the participants in both treatment groups.

Conditions

Interventions

BIOLOGICAL

Hematopoietic stem cell transplant

Intravenous infusion of hematopoietic stem cells from a donor.

DRUG

Ruxolitinib

Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).

DRUG

Hydroxyurea

Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Vikas Gupta, M.D. · Princess Margaret Cancer Centre

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217356 on ClinicalTrials.gov